Subtopic Deep Dive
Neurofibromin as NF1 Tumor Suppressor
Research Guide
What is Neurofibromin as NF1 Tumor Suppressor?
Neurofibromin is the protein encoded by the NF1 gene that acts as a Ras-GTPase activating protein (Ras-GAP) to suppress tumor formation in Neurofibromatosis Type 1.
NF1 mutations lead to loss of neurofibromin function, causing uncontrolled Ras signaling and tumor development in neural crest-derived tissues. Mouse models demonstrate developmental abnormalities from targeted NF1 disruption (Brannan et al., 1994, 641 citations). Neuronal NF1 ablation induces cerebral cortex defects and gliosis (Zhu et al., 2001, 610 citations).
Why It Matters
Understanding neurofibromin's Ras-GAP activity guides therapies targeting downstream MAPK/mTOR pathways in NF1 tumors like neurofibromas and malignant peripheral nerve sheath tumors. Johannessen et al. (2005, 588 citations) showed NF1 regulates TSC2 and mTOR, linking it to rapamycin-sensitive pathways. Shannon et al. (1994, 447 citations) demonstrated NF1 loss in myeloid malignancies, informing leukemia risk in NF1 patients. These insights support MEK inhibitors and vascular management strategies (Oderich et al., 2007, 380 citations).
Key Research Challenges
Haploinsufficiency Mechanisms
NF1 heterozygosity causes phenotypes before full tumor suppressor loss, complicating models. Brannan et al. (1994) found heart and neural crest defects in Nf1+/- mice. Zhu et al. (2001) linked neuronal haploinsufficiency to cortex abnormalities.
Downstream Pathway Crosstalk
Neurofibromin impacts Ras, mTOR, and MAPK, but interactions remain unclear. Johannessen et al. (2005) revealed NF1-TSC2-mTOR regulation. Pfister et al. (2008) identified BRAF duplication in astrocytomas activating MAPK.
Mutation Functional Impacts
Diverse NF1 mutations variably disrupt Ras-GAP activity. Shen et al. (1996, 374 citations) cataloged NF1 genetics. Shannon et al. (1994) showed somatic NF1 loss in myeloid disorders.
Essential Papers
Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues.
Camilynn I. Brannan, Archibald S. Perkins, Kristine S. Vogel et al. · 1994 · Genes & Development · 641 citations
The neurofibromatosis (NF1) gene shows significant homology to mammalian GAP and is an important regulator of the ras signal transduction pathway. To study the function of NF1 in normal development...
Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain
Yuan Zhu, Mario I. Romero‐Ortega, Pritam Ghosh et al. · 2001 · Genes & Development · 610 citations
Neurofibromatosis type 1 (NF1) is a prevalent genetic disorder that affects growth properties of neural-crest-derived cell populations. In addition, approximately one-half of NF1 patients exhibit l...
The NF1 tumor suppressor critically regulates TSC2 and mTOR
Cory M. Johannessen, Elizabeth E. Reczek, Marianne F. James et al. · 2005 · Proceedings of the National Academy of Sciences · 588 citations
Loss-of-function mutations in the NF1 tumor suppressor gene underlie the familial cancer syndrome neurofibromatosis type I (NF1). The NF1 -encoded protein, neurofibromin, functions as a Ras-GTPase ...
BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas
Stefan M. Pfister, Wibke G. Janzarik, Marc Remke et al. · 2008 · Journal of Clinical Investigation · 509 citations
The molecular pathogenesis of pediatric astrocytomas is still poorly understood. To further understand the genetic abnormalities associated with these tumors, we performed a genome-wide analysis of...
Inherited pancreatic endocrine tumor syndromes: Advances in molecular pathogenesis, diagnosis, management, and controversies
Robert T. Jensen, Marc J. Berna, David Bingham et al. · 2008 · Cancer · 480 citations
Pancreatic endocrine tumors (PETs) can occur as part of 4 inherited disorders, including Multiple Endocrine Neoplasia type 1 (MEN1), von Hippel-Lindau disease (VHL), neurofibromatosis 1 (NF-1) (von...
Cortical Actin Organization: Lessons from ERM (Ezrin/Radixin/Moesin) Proteins
Sachiko Tsukita, Shigenobu Yonemura · 1999 · Journal of Biological Chemistry · 463 citations
ezrin/radixin/moesin ERM-binding phosphoprotein of 50 kDa protein-tyrosine phosphatase Na+/H+ exchanger regulatory factor protein kinase A ERM-association domain phosphatidylinositol 4,5-bisphospha...
Loss of The Normal NF1 Allele from the Bone Marrow of Children with Type 1 Neurofibromatosis and Malignant Myeloid Disorders
Kevin Shannon, P. O’Connell, George A. Martin et al. · 1994 · New England Journal of Medicine · 447 citations
These data provide evidence of NF1 may function as a tumor-suppressor allele in malignant myeloid diseases in children with NF-1 and that neurofibromin is a regulator of ras in early myelopoiesis.
Reading Guide
Foundational Papers
Start with Brannan et al. (1994, 641 citations) for NF1 knockout phenotypes establishing Ras pathway role; follow with Johannessen et al. (2005, 588 citations) for mTOR linkage; Zhu et al. (2001, 610 citations) for neuronal effects.
Recent Advances
Farid et al. (2014, 349 citations) on MPNST management; Pfister et al. (2008, 509 citations) on MAPK in astrocytomas.
Core Methods
Ras-GTP assays, conditional knockouts (Brannan 1994; Zhu 2001), genome-wide copy number analysis (Pfister 2008), somatic mutation detection in tumors (Shannon 1994).
How PapersFlow Helps You Research Neurofibromin as NF1 Tumor Suppressor
Discover & Search
Research Agent uses searchPapers and citationGraph to map NF1 Ras-GAP literature from Brannan et al. (1994, 641 citations), revealing forward citations on mouse models. exaSearch finds recent NF1-mTOR extensions; findSimilarPapers clusters papers like Johannessen et al. (2005).
Analyze & Verify
Analysis Agent applies readPaperContent to extract Ras-GAP domains from Zhu et al. (2001), then verifyResponse with CoVe checks claims against abstracts. runPythonAnalysis statistically compares mutation frequencies across NF1 papers using pandas; GRADE grades evidence for haploinsufficiency strength.
Synthesize & Write
Synthesis Agent detects gaps in NF1-mTOR crosstalk post-Johannessen et al. (2005) via contradiction flagging. Writing Agent uses latexEditText and latexSyncCitations to draft reviews citing 10+ papers, latexCompile for figures, exportMermaid for Ras pathway diagrams.
Use Cases
"Analyze NF1 mutation rates in schwannomas from 1990-2010 papers"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas aggregation of mutation data from Shannon et al. 1994 and Shen et al. 1996) → CSV table of rates by tumor type.
"Write LaTeX review on neurofibromin Ras-GAP in NF1 tumors"
Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (Brannan 1994, Johannessen 2005) → latexCompile → PDF with bibliography.
"Find code for NF1 mouse model simulations"
Research Agent → paperExtractUrls (Zhu 2001) → Code Discovery → paperFindGithubRepo → githubRepoInspect → Python scripts modeling Ras signaling.
Automated Workflows
Deep Research workflow scans 50+ NF1 papers via searchPapers, structures report on Ras-GAP evolution from Brannan (1994) to Johannessen (2005). DeepScan applies 7-step CoVe to verify haploinsufficiency claims in Zhu (2001), with GRADE checkpoints. Theorizer generates hypotheses on NF1-mTOR therapies from pathway papers.
Frequently Asked Questions
What defines neurofibromin as NF1 tumor suppressor?
Neurofibromin encodes a Ras-GAP that hydrolyzes Ras-GTP to curb cell proliferation; NF1 loss deregulates Ras (Brannan et al., 1994).
What methods study neurofibromin function?
Mouse knockouts reveal developmental roles (Brannan et al., 1994; Zhu et al., 2001); biochemical assays confirm Ras-GAP activity (Johannessen et al., 2005).
What are key papers?
Brannan et al. (1994, 641 citations) on Nf1 knockout mice; Johannessen et al. (2005, 588 citations) on NF1-mTOR; Zhu et al. (2001, 610 citations) on neuronal ablation.
What open problems exist?
Unclear how NF1 haploinsufficiency drives tumors pre-second hit; variable mutation impacts on Ras vs. mTOR need clarification (Shen et al., 1996).
Research Neurofibromatosis and Schwannoma Cases with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Neurofibromin as NF1 Tumor Suppressor with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers